Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lasmiditan

- PMLiVE

Diabetes care recognised at UK awards

Joint working between pharma, NHS and patient organisations key among winners at QiC Diabetes 2012

- PMLiVE

Lilly’s gastric cancer prospect clears phase III trial

Ramucirumab improved both overall and progress-free survival

- PMLiVE

Lilly, Roche drugs selected for Alzheimer’s prevention study

Large-scale study will involve Roche's gantenerumab and Lilly's solanezumab

- PMLiVE

Independent analysis raises hope for Lilly’s Alzheimer’s drug

Pooled results show solanezumab slowed cognitive decline in subgroup by 34 per cent

JDRF and Lilly take diabetes education to secondary schools

The partnership will use a new resource to teach students about type 1 diabetes

EMA recommends Lilly’s erectile dysfunction drug for enlarged prostate

Cialis would be first drug available in Europe for both ED and BPH

- PMLiVE

Boehringer-Lilly tap into behavioural change for online diabetes programme

Part of the partners' Tradjenta marketing, My Well Planner offers personalised educational resources

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

- PMLiVE

Lilly launches branded app for emergency diabetes medicine

US-only Lilly Glucagon iPhone and iPad app shows carers how to use the hypoglycaemia treatment

- PMLiVE

Lilly appoints Michael Harrington SVP and general counsel

Replaces Robert Armitage who retires from the pharma company

Lilly drops touted Zyprexa successor for use in schizophrenia

Pomaglumetad methionil disappoints in phase III

- PMLiVE

Lilly’s Alzheimer’s drug solanezumab stumbles, but doesn’t fall in phase III

Fails to show significant benefit, but data holds some consolation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links